Liquid Stable Kit Determines Homocysteine in Serum and Plasma
|
By LabMedica International staff writers Posted on 20 Jun 2012 |
A liquid stable homocysteine kit provides a convenient and accurate method for the determination of homocysteine in human serum and plasma. Homocysteine is an indicator of a number of disease markers and should be an integral part of a laboratory’s testing menu.
Produced by the demethylation of methionine, homocysteine is converted by vitamins B6, B12, and folic acid into useful substances. If the body is suffering from a lack of these nutrients, the process of homocysteine conversion is affected and levels rise. Elevated levels of homocysteine (Hyperhomocysteinemia) are a risk factor for a number of health problems including cardiovascular disease (CVD), stroke, dementia, complicated pregnancy, and osteoporosis.
Low levels of this analyte can also prove to be detrimental. Homocysteine is a necessary component for the production of protein and tissue within the body, therefore levels should not be lower than 5 µmol/L.
The Randox (Crumlin, United Kingdom) kit can aid in the diagnosis of both elevated and depleted levels of homocysteine and the diverse range of potential health problems associated with these.
The kit has liquid ready-to-use reagents requiring no preparation for ease of use and the elimination of reconstitution errors. It includes standards for optimal user convenience. The good on-board stability of 28 days minimizes reagent waste. The measuring range of 1.74 µmol/L to 47.9 µmol/L, allows both normal and abnormal values to be accurately measured. There is limited interference from bilirubin, haemoglobin, intralipids, and triglycerides, enabling optimum performance and the generation of precise, reliable results. A correlation coefficient of 0.98 was obtained against another commercially available kit. Protocols are available for a range of analyzers.
Related Links:
Randox
Produced by the demethylation of methionine, homocysteine is converted by vitamins B6, B12, and folic acid into useful substances. If the body is suffering from a lack of these nutrients, the process of homocysteine conversion is affected and levels rise. Elevated levels of homocysteine (Hyperhomocysteinemia) are a risk factor for a number of health problems including cardiovascular disease (CVD), stroke, dementia, complicated pregnancy, and osteoporosis.
Low levels of this analyte can also prove to be detrimental. Homocysteine is a necessary component for the production of protein and tissue within the body, therefore levels should not be lower than 5 µmol/L.
The Randox (Crumlin, United Kingdom) kit can aid in the diagnosis of both elevated and depleted levels of homocysteine and the diverse range of potential health problems associated with these.
The kit has liquid ready-to-use reagents requiring no preparation for ease of use and the elimination of reconstitution errors. It includes standards for optimal user convenience. The good on-board stability of 28 days minimizes reagent waste. The measuring range of 1.74 µmol/L to 47.9 µmol/L, allows both normal and abnormal values to be accurately measured. There is limited interference from bilirubin, haemoglobin, intralipids, and triglycerides, enabling optimum performance and the generation of precise, reliable results. A correlation coefficient of 0.98 was obtained against another commercially available kit. Protocols are available for a range of analyzers.
Related Links:
Randox
Latest Clinical Chem. News
- Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
- Blood Test Detects More High-Risk Prostate Cancers Than PSA
- Rapid Blood Test Aids Diagnosis of Acute Ischemic Stroke
- Blood-Based Alzheimer’s Testing Platform Offers Rapid Results
- Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth
- Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
- Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
- Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging
- Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
- Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Channels
Molecular Diagnostics
view channel
Ultrasensitive ctDNA Assay Detects MRD in Breast, Colorectal, Renal Cancers
Minimal residual disease testing is increasingly used to guide adjuvant therapy and surveillance in solid tumors, but detecting very low levels of circulating tumor DNA remains challenging in routine practice.... Read more
Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease
Women show distinct susceptibility to infectious diseases and higher rates of autoimmune disorders, yet the molecular drivers remain unclear. This gap has limited sex-specific diagnostic and prognostic tools.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Airway Immune Signature May Predict Tuberculosis Progression Risk
Tuberculosis remains difficult to predict and prevent, despite widespread exposure worldwide. An estimated quarter of the global population has been infected with Mycobacterium tuberculosis, yet only a... Read more
Lung Immune Profiling Reveals Distinct Severe Pneumonia Subtypes
Severe pneumonia often progresses to respiratory failure requiring intensive care and mechanical ventilation. Despite similar clinical presentations, outcomes vary widely, complicating decisions on an... Read moreMicrobiology
view channel
Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read more
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Agreement Supports pTau217-Based Alzheimer’s Blood Test Development
As disease-modifying therapies for Alzheimer’s disease expand, accessible diagnostics are increasingly needed to identify patients earlier. Current confirmatory methods, including PET imaging and cerebrospinal... Read more








